# US 2024/0197837 A1 · Gene editing of deep intronic mutations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197837 A1
- Document ID: US20240197837A1
- Status: Published application
- Kind: A1
- Application number: 18/399,364
- Filed: 2023-12-28
- Published: 2024-06-20
- Earliest claimed: 2015-05-16
- Assignees: Genzyme Corporation
- Applicants: Genzyme Corporation
- Inventors: Guoxiang RUAN; Abraham SCARIA
- Web page: https://patentgrep.com/patent/US20240197837A1

## CPC

- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/12: for electrolyte homeostasis
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are compositions, methods, kits, and viral particles for treating a disease or disorder associated with a deep intronic mutation using an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)—CRISPR associated (Cas) (CRISPR-Cas) system. In some aspects, provided herein is a self-limiting CRISPER-Cas system.

## Claims

### Claim at position 1

1-458. (canceled)

### Claim 459

A composition for limiting expression of Cas9 protein in a cell comprising:
a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site, wherein the first target site is located in the cell's genome,
b) a Cas expression cassette, wherein the Cas expression cassette comprises:
i) a nucleotide sequence encoding a Cas9 protein, and
ii) a cleavage site that is a nucleotide sequence comprising the first target site,
wherein the cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.

### Claim 460 (depends on 459)

The composition of claim 459, wherein the Cas expression cassette further comprises one or more regulatory control elements, optionally wherein the one or more regulatory control elements is a promoter, operably linked to the nucleotide sequence encoding the Cas9 protein, wherein the cleavage site is between the one or more regulatory control elements and the nucleotide sequence encoding the Cas9 protein.

### Claim 461 (depends on 459)

The composition of claim 459, wherein the Cas expression cassette further comprises a polyadenylation (polyA) sequence operably linked to the nucleotide sequence encoding the Cas9 protein, wherein the cleavage site is between the polyA sequence and the nucleotide sequencing encoding the Cas9 protein.

### Claim 462 (depends on 459)

The composition of claim 459, wherein the nucleic acid encoding at least one guide RNA and the Cas expression cassette are located on the same vector.

### Claim 463 (depends on 459)

The composition of claim 459, wherein the nucleic acid encoding at least one guide RNA and the Cas expression cassette are located on different vectors.

### Claim 464 (depends on 463)

The composition of claim 463, wherein the vector comprising the Cas expression cassette and the vector comprising the nucleic acid encoding at least one guide RNA are independently selected from a recombinant adeno-associated virus (rAAV) vector, a recombinant adenoviral vector, a recombinant lentiviral vector, or a recombinant herpes simplex virus (HSV) vector.

### Claim 465 (depends on 464)

The composition of claim 464, wherein the vector comprising the Cas expression cassette and the vector comprising the nucleic acid encoding at least one guide RNA are both rAAV vectors.

### Claim 466 (depends on 459)

The composition of claim 459, wherein the at least one guide RNA further comprises a second guide RNA that hybridizes to a second target site, wherein the second target site is located in the cell's genome.

### Claim 467

A composition for limiting expression of Cas9 protein in a cell comprising:
a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site and a second guide RNA that hybridizes to a second target site,
wherein the first and second target sites are located in the cell's genome,
b) a Cas expression cassette, wherein the Cas expression cassette comprises:
i) a nucleotide sequence encoding a Cas9 protein, and
ii) a first cleavage site that is a nucleotide sequence comprising the first or second target site,
wherein the first cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.

### Claim 468 (depends on 467)

The composition of claim 467, wherein the Cas expression cassette further comprises a second cleavage site that is a nucleotide sequence comprising the first or second target site,
wherein the second cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.

### Claim 469 (depends on 468)

The composition of claim 468, wherein the Cas expression cassette further comprises one or more regulatory control elements, optionally wherein the one or more regulatory control elements is a promoter, operably linked to the nucleotide sequence encoding the Cas9 protein, wherein the first cleavage site is between the one or more regulatory control elements and the nucleotide sequence encoding the Cas9 protein.

### Claim 470 (depends on 468)

The composition of claim 468, wherein the Cas expression cassette further comprises a polyadenylation (polyA) sequence operably linked to the nucleotide sequence encoding the Cas9 protein, wherein the second cleavage site is between the polyA sequence and the nucleotide sequencing encoding the Cas9 protein.

### Claim 471 (depends on 468)

The composition of claim 468, wherein the first and second cleavage sites contain the same target sites.

### Claim 472 (depends on 468)

The composition of claim 468, wherein the first and second cleavage sites contain different target sites.

### Claim 473 (depends on 467)

The composition of claim 467, wherein the first and second target sites are located on opposite strands of a target DNA.

### Claim 474 (depends on 473)

The composition of claim 473, wherein the target DNA comprises a gene comprising a deep intronic mutation.

### Claim 475

A composition for limiting expression of Cas9 protein in a cell comprising:
a) a nucleic acid encoding at least one guide RNA comprising a first guide RNA that hybridizes to a first target site and a second guide RNA that hybridizes to a second target site,
wherein the first and second target sites are located in the cell's genome and located on opposite strands of a target gene,
wherein the target gene comprises a gene comprising a deep intronic mutation; and
b) a Cas expression cassette, wherein the Cas expression cassette comprises:
i) a nucleotide sequence encoding a Cas9 protein, and
ii) a first cleavage site that is a nucleotide sequence comprising the first or second target site,
wherein the first cleavage site is capable of being cleaved by the Cas9 protein to thereby reduce expression of the Cas9 protein, as compared to expression of the Cas9 protein prior to cleavage of the Cas expression cassette.

### Claim 476 (depends on 475)

The composition of claim 475, wherein the gene comprising a deep intronic mutation is CEP290.

### Claim 477 (depends on 476)

The composition of claim 476, wherein the deep intronic mutation is a c.2991+1655A>G mutation.
